Biogen to acquire Reata Pharmaceuticals in $7 billion deal

Biogen on Friday said it would acquire Reata Pharmaceuticals, the maker of an approved therapy for a rare neurological condition, in a deal worth $7.3 billion.

The transaction price of $172.50 per share is a nearly 60% premium from Reata’s share price at Thursday’s close. The deal is expected to close by the end of the year.

Reata, based in Plano, Texas, won its first approval in February for a drug that treats Friedreich’s ataxia. The drug, called Skyclarys, was the first treatment to be authorized by the Food and Drug Administration for the condition, which causes progressive damage to the brain, nervous system, and muscles. The average life expectancy for a person with FA is in the mid-30s. 

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In